OSE Immunotherapeutics And Servier Join Forces In Auto-Immune Field

 
• By Lubna Ahmed and Sten Stovall

French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.

OSE Immunotherapeutics SA and France's second largest drug maker Servier SA have agreed to develop and commercialize the biotech's IL-7 antagonist Effi-7 in ulcerative colitis in a deal that could be worth up to €272m to the newly formed group.

The pact, announced Dec. 28, will see privately owned Servier pay OSE Immunotherapeutics €10.25m ($10.71m) for an option to license...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

More from Scrip

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.